Phage therapy or viral phage therapy is the therapeutic use of bacteriophages to treat pathogenic bacterial infections. Bacteriophages, known as phages, are a form of viruses. Phages attach to bacterial cells, and inject a viral genome into the cell.
This report provides a complete quantitative data and qualitative analysis on the global market for Bacteriophage Therapy. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.
Prior to COVID-19, the global market for Bacteriophage Therapy was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Bacteriophage Therapy is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.
This report covers market size and forecasts of Bacteriophage Therapy, including the following market information:
Global Bacteriophage Therapy Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Bacteriophage Therapy Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Bacteriophage Therapy Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Bacteriophage Therapy Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include Armata Pharmaceuticals, Inc., Eliava Biopreparations Ltd., Pherecydes Pharma, Intralytix, Inc., Phagelux Inc., Nextbiotics, InnoPhage, Ltd, Locus Biosciences, Inc., TechnoPhage, Eligo Bioscience SA, Phagomed Biopharma GmbH., PhagePro, Inc., Adaptive Phage Therapeutics, Inc., EnBiotix, Inc., Intodeworld, Inc., BiomX Ltd., Phi Therapeutics, Fixed-phage Ltd., Micreos BV, ContraFect Corporation, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Oral
Topical
Parenteral
Based on the Application:
Organ Transplantation
Bacterial Infections
Alcoholic Hepatitis
Other
This report provides a complete quantitative data and qualitative analysis on the global market for Bacteriophage Therapy. Market size is analysed by country, product type, application, and competitors. Expanded coverage includes additional end-user industry breakdowns and in-depth producer profiles.
Prior to COVID-19, the global market for Bacteriophage Therapy was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 2021–2026, whereas post-COVID-19 scenario, the market for Bacteriophage Therapy is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026.
This report covers market size and forecasts of Bacteriophage Therapy, including the following market information:
Global Bacteriophage Therapy Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Bacteriophage Therapy Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Bacteriophage Therapy Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
Global Bacteriophage Therapy Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
Key market players
Major competitors identified in this market include Armata Pharmaceuticals, Inc., Eliava Biopreparations Ltd., Pherecydes Pharma, Intralytix, Inc., Phagelux Inc., Nextbiotics, InnoPhage, Ltd, Locus Biosciences, Inc., TechnoPhage, Eligo Bioscience SA, Phagomed Biopharma GmbH., PhagePro, Inc., Adaptive Phage Therapeutics, Inc., EnBiotix, Inc., Intodeworld, Inc., BiomX Ltd., Phi Therapeutics, Fixed-phage Ltd., Micreos BV, ContraFect Corporation, etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Oral
Topical
Parenteral
Based on the Application:
Organ Transplantation
Bacterial Infections
Alcoholic Hepatitis
Other
1.1 Research Scope
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Bacteriophage Therapy Industry
1.7 COVID-19 Impact: Bacteriophage Therapy Market Trends
2 Global Bacteriophage Therapy Quarterly Market Size Analysis
2.1 Bacteriophage Therapy Business Impact Assessment - COVID-19
2.1.1 Global Bacteriophage Therapy Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Bacteriophage Therapy Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
3.1 By Players, Global Bacteriophage Therapy Quarterly Market Size, 2019 VS 2020
3.2 By Players, Bacteriophage Therapy Headquarters and Area Served
3.3 Date of Key Players Enter into Bacteriophage Therapy Market
3.4 Key Players Bacteriophage Therapy Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Bacteriophage Therapy Segments, By Type
4.1 Introduction
1.4.1 Oral
1.4.2 Topical
1.4.3 Parenteral
4.2 By Type, Global Bacteriophage Therapy Market Size, 2019-2021
5 Impact of Covid-19 on Bacteriophage Therapy Segments, By Application
5.1 Overview
5.5.1 Organ Transplantation
5.5.2 Bacterial Infections
5.5.3 Alcoholic Hepatitis
5.5.4 Other
5.2 By Application, Global Bacteriophage Therapy Market Size, 2019-2021
5.2.1 By Application, Global Bacteriophage Therapy Market Size by Application, 2019-2021
6 Geographic Analysis
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 Company Profiles
7.1 Armata Pharmaceuticals, Inc.
7.1.1 Armata Pharmaceuticals, Inc. Business Overview
7.1.2 Armata Pharmaceuticals, Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.1.3 Armata Pharmaceuticals, Inc. Bacteriophage Therapy Product Introduction
7.1.4 Armata Pharmaceuticals, Inc. Response to COVID-19 and Related Developments
7.2 Eliava Biopreparations Ltd.
7.2.1 Eliava Biopreparations Ltd. Business Overview
7.2.2 Eliava Biopreparations Ltd. Bacteriophage Therapy Quarterly Revenue, 2020
7.2.3 Eliava Biopreparations Ltd. Bacteriophage Therapy Product Introduction
7.2.4 Eliava Biopreparations Ltd. Response to COVID-19 and Related Developments
7.3 Pherecydes Pharma
7.3.1 Pherecydes Pharma Business Overview
7.3.2 Pherecydes Pharma Bacteriophage Therapy Quarterly Revenue, 2020
7.3.3 Pherecydes Pharma Bacteriophage Therapy Product Introduction
7.3.4 Pherecydes Pharma Response to COVID-19 and Related Developments
7.4 Intralytix, Inc.
7.4.1 Intralytix, Inc. Business Overview
7.4.2 Intralytix, Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.4.3 Intralytix, Inc. Bacteriophage Therapy Product Introduction
7.4.4 Intralytix, Inc. Response to COVID-19 and Related Developments
7.5 Phagelux Inc.
7.5.1 Phagelux Inc. Business Overview
7.5.2 Phagelux Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.5.3 Phagelux Inc. Bacteriophage Therapy Product Introduction
7.5.4 Phagelux Inc. Response to COVID-19 and Related Developments
7.6 Nextbiotics
7.6.1 Nextbiotics Business Overview
7.6.2 Nextbiotics Bacteriophage Therapy Quarterly Revenue, 2020
7.6.3 Nextbiotics Bacteriophage Therapy Product Introduction
7.6.4 Nextbiotics Response to COVID-19 and Related Developments
7.7 InnoPhage, Ltd
7.7.1 InnoPhage, Ltd Business Overview
7.7.2 InnoPhage, Ltd Bacteriophage Therapy Quarterly Revenue, 2020
7.7.3 InnoPhage, Ltd Bacteriophage Therapy Product Introduction
7.7.4 InnoPhage, Ltd Response to COVID-19 and Related Developments
7.8 Locus Biosciences, Inc.
7.8.1 Locus Biosciences, Inc. Business Overview
7.8.2 Locus Biosciences, Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.8.3 Locus Biosciences, Inc. Bacteriophage Therapy Product Introduction
7.8.4 Locus Biosciences, Inc. Response to COVID-19 and Related Developments
7.9 TechnoPhage
7.9.1 TechnoPhage Business Overview
7.9.2 TechnoPhage Bacteriophage Therapy Quarterly Revenue, 2020
7.9.3 TechnoPhage Bacteriophage Therapy Product Introduction
7.9.4 TechnoPhage Response to COVID-19 and Related Developments
7.10 Eligo Bioscience SA
7.10.1 Eligo Bioscience SA Business Overview
7.10.2 Eligo Bioscience SA Bacteriophage Therapy Quarterly Revenue, 2020
7.10.3 Eligo Bioscience SA Bacteriophage Therapy Product Introduction
7.10.4 Eligo Bioscience SA Response to COVID-19 and Related Developments
7.11 Phagomed Biopharma GmbH.
7.11.1 Phagomed Biopharma GmbH. Business Overview
7.11.2 Phagomed Biopharma GmbH. Bacteriophage Therapy Quarterly Revenue, 2020
7.11.3 Phagomed Biopharma GmbH. Bacteriophage Therapy Product Introduction
7.11.4 Phagomed Biopharma GmbH. Response to COVID-19 and Related Developments
7.12 PhagePro, Inc.
7.12.1 PhagePro, Inc. Business Overview
7.12.2 PhagePro, Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.12.3 PhagePro, Inc. Bacteriophage Therapy Product Introduction
7.12.4 PhagePro, Inc. Response to COVID-19 and Related Developments
7.13 Adaptive Phage Therapeutics, Inc.
7.13.1 Adaptive Phage Therapeutics, Inc. Business Overview
7.13.2 Adaptive Phage Therapeutics, Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.13.3 Adaptive Phage Therapeutics, Inc. Bacteriophage Therapy Product Introduction
7.13.4 Adaptive Phage Therapeutics, Inc. Response to COVID-19 and Related Developments
7.14 EnBiotix, Inc.
7.14.1 EnBiotix, Inc. Business Overview
7.14.2 EnBiotix, Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.14.3 EnBiotix, Inc. Bacteriophage Therapy Product Introduction
7.14.4 EnBiotix, Inc. Response to COVID-19 and Related Developments
7.15 Intodeworld, Inc.
7.15.1 Intodeworld, Inc. Business Overview
7.15.2 Intodeworld, Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.15.3 Intodeworld, Inc. Bacteriophage Therapy Product Introduction
7.15.4 Intodeworld, Inc. Response to COVID-19 and Related Developments
7.16 BiomX Ltd.
7.16.1 BiomX Ltd. Business Overview
7.16.2 BiomX Ltd. Bacteriophage Therapy Quarterly Revenue, 2020
7.16.3 BiomX Ltd. Bacteriophage Therapy Product Introduction
7.16.4 BiomX Ltd. Response to COVID-19 and Related Developments
7.17 Phi Therapeutics
7.17.1 Phi Therapeutics Business Overview
7.17.2 Phi Therapeutics Bacteriophage Therapy Quarterly Revenue, 2020
7.17.3 Phi Therapeutics Bacteriophage Therapy Product Introduction
7.17.4 Phi Therapeutics Response to COVID-19 and Related Developments
7.18 Fixed-phage Ltd.
7.18.1 Fixed-phage Ltd. Business Overview
7.18.2 Fixed-phage Ltd. Bacteriophage Therapy Quarterly Revenue, 2020
7.18.3 Fixed-phage Ltd. Bacteriophage Therapy Product Introduction
7.18.4 Fixed-phage Ltd. Response to COVID-19 and Related Developments
7.19 Micreos BV
7.19.1 Micreos BV Business Overview
7.19.2 Micreos BV Bacteriophage Therapy Quarterly Revenue, 2020
7.19.3 Micreos BV Bacteriophage Therapy Product Introduction
7.19.4 Micreos BV Response to COVID-19 and Related Developments
7.20 ContraFect Corporation
7.20.1 ContraFect Corporation Business Overview
7.20.2 ContraFect Corporation Bacteriophage Therapy Quarterly Revenue, 2020
7.20.3 ContraFect Corporation Bacteriophage Therapy Product Introduction
7.20.4 ContraFect Corporation Response to COVID-19 and Related Developments
8 Key Findings
9 Appendix
9.1 About US
9.2 Disclaimer
1.2 Market Segmentation
1.3 Research Objectives
1.4 Research Methodology
1.4.1 Research Process
1.4.2 Data Triangulation
1.4.3 Research Approach
1.4.4 Base Year
1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.5.2 Covid-19 Impact: Commodity Prices Indices
1.5.3 Covid-19 Impact: Global Major Government Policy
1.6 The Covid-19 Impact on Bacteriophage Therapy Industry
1.7 COVID-19 Impact: Bacteriophage Therapy Market Trends
2 Global Bacteriophage Therapy Quarterly Market Size Analysis
2.1 Bacteriophage Therapy Business Impact Assessment - COVID-19
2.1.1 Global Bacteriophage Therapy Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
2.2 Global Bacteriophage Therapy Quarterly Market Size 2020-2021
2.3 COVID-19-Driven Market Dynamics and Factor Analysis
2.3.1 Drivers
2.3.2 Restraints
2.3.3 Opportunities
2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
3.1 By Players, Global Bacteriophage Therapy Quarterly Market Size, 2019 VS 2020
3.2 By Players, Bacteriophage Therapy Headquarters and Area Served
3.3 Date of Key Players Enter into Bacteriophage Therapy Market
3.4 Key Players Bacteriophage Therapy Product Offered
3.5 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Bacteriophage Therapy Segments, By Type
4.1 Introduction
1.4.1 Oral
1.4.2 Topical
1.4.3 Parenteral
4.2 By Type, Global Bacteriophage Therapy Market Size, 2019-2021
5 Impact of Covid-19 on Bacteriophage Therapy Segments, By Application
5.1 Overview
5.5.1 Organ Transplantation
5.5.2 Bacterial Infections
5.5.3 Alcoholic Hepatitis
5.5.4 Other
5.2 By Application, Global Bacteriophage Therapy Market Size, 2019-2021
5.2.1 By Application, Global Bacteriophage Therapy Market Size by Application, 2019-2021
6 Geographic Analysis
6.1 Introduction
6.2 North America
6.2.1 Macroeconomic Indicators of US
6.2.2 US
6.2.3 Canada
6.3 Europe
6.3.1 Macroeconomic Indicators of Europe
6.3.2 Germany
6.3.3 France
6.3.4 UK
6.3.5 Italy
6.4 Asia-Pacific
6.4.1 Macroeconomic Indicators of Asia-Pacific
6.4.2 China
6.4.3 Japan
6.4.4 South Korea
6.4.5 India
6.4.6 ASEAN
6.5 Rest of World
6.5.1 Latin America
6.5.2 Middle East and Africa
7 Company Profiles
7.1 Armata Pharmaceuticals, Inc.
7.1.1 Armata Pharmaceuticals, Inc. Business Overview
7.1.2 Armata Pharmaceuticals, Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.1.3 Armata Pharmaceuticals, Inc. Bacteriophage Therapy Product Introduction
7.1.4 Armata Pharmaceuticals, Inc. Response to COVID-19 and Related Developments
7.2 Eliava Biopreparations Ltd.
7.2.1 Eliava Biopreparations Ltd. Business Overview
7.2.2 Eliava Biopreparations Ltd. Bacteriophage Therapy Quarterly Revenue, 2020
7.2.3 Eliava Biopreparations Ltd. Bacteriophage Therapy Product Introduction
7.2.4 Eliava Biopreparations Ltd. Response to COVID-19 and Related Developments
7.3 Pherecydes Pharma
7.3.1 Pherecydes Pharma Business Overview
7.3.2 Pherecydes Pharma Bacteriophage Therapy Quarterly Revenue, 2020
7.3.3 Pherecydes Pharma Bacteriophage Therapy Product Introduction
7.3.4 Pherecydes Pharma Response to COVID-19 and Related Developments
7.4 Intralytix, Inc.
7.4.1 Intralytix, Inc. Business Overview
7.4.2 Intralytix, Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.4.3 Intralytix, Inc. Bacteriophage Therapy Product Introduction
7.4.4 Intralytix, Inc. Response to COVID-19 and Related Developments
7.5 Phagelux Inc.
7.5.1 Phagelux Inc. Business Overview
7.5.2 Phagelux Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.5.3 Phagelux Inc. Bacteriophage Therapy Product Introduction
7.5.4 Phagelux Inc. Response to COVID-19 and Related Developments
7.6 Nextbiotics
7.6.1 Nextbiotics Business Overview
7.6.2 Nextbiotics Bacteriophage Therapy Quarterly Revenue, 2020
7.6.3 Nextbiotics Bacteriophage Therapy Product Introduction
7.6.4 Nextbiotics Response to COVID-19 and Related Developments
7.7 InnoPhage, Ltd
7.7.1 InnoPhage, Ltd Business Overview
7.7.2 InnoPhage, Ltd Bacteriophage Therapy Quarterly Revenue, 2020
7.7.3 InnoPhage, Ltd Bacteriophage Therapy Product Introduction
7.7.4 InnoPhage, Ltd Response to COVID-19 and Related Developments
7.8 Locus Biosciences, Inc.
7.8.1 Locus Biosciences, Inc. Business Overview
7.8.2 Locus Biosciences, Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.8.3 Locus Biosciences, Inc. Bacteriophage Therapy Product Introduction
7.8.4 Locus Biosciences, Inc. Response to COVID-19 and Related Developments
7.9 TechnoPhage
7.9.1 TechnoPhage Business Overview
7.9.2 TechnoPhage Bacteriophage Therapy Quarterly Revenue, 2020
7.9.3 TechnoPhage Bacteriophage Therapy Product Introduction
7.9.4 TechnoPhage Response to COVID-19 and Related Developments
7.10 Eligo Bioscience SA
7.10.1 Eligo Bioscience SA Business Overview
7.10.2 Eligo Bioscience SA Bacteriophage Therapy Quarterly Revenue, 2020
7.10.3 Eligo Bioscience SA Bacteriophage Therapy Product Introduction
7.10.4 Eligo Bioscience SA Response to COVID-19 and Related Developments
7.11 Phagomed Biopharma GmbH.
7.11.1 Phagomed Biopharma GmbH. Business Overview
7.11.2 Phagomed Biopharma GmbH. Bacteriophage Therapy Quarterly Revenue, 2020
7.11.3 Phagomed Biopharma GmbH. Bacteriophage Therapy Product Introduction
7.11.4 Phagomed Biopharma GmbH. Response to COVID-19 and Related Developments
7.12 PhagePro, Inc.
7.12.1 PhagePro, Inc. Business Overview
7.12.2 PhagePro, Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.12.3 PhagePro, Inc. Bacteriophage Therapy Product Introduction
7.12.4 PhagePro, Inc. Response to COVID-19 and Related Developments
7.13 Adaptive Phage Therapeutics, Inc.
7.13.1 Adaptive Phage Therapeutics, Inc. Business Overview
7.13.2 Adaptive Phage Therapeutics, Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.13.3 Adaptive Phage Therapeutics, Inc. Bacteriophage Therapy Product Introduction
7.13.4 Adaptive Phage Therapeutics, Inc. Response to COVID-19 and Related Developments
7.14 EnBiotix, Inc.
7.14.1 EnBiotix, Inc. Business Overview
7.14.2 EnBiotix, Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.14.3 EnBiotix, Inc. Bacteriophage Therapy Product Introduction
7.14.4 EnBiotix, Inc. Response to COVID-19 and Related Developments
7.15 Intodeworld, Inc.
7.15.1 Intodeworld, Inc. Business Overview
7.15.2 Intodeworld, Inc. Bacteriophage Therapy Quarterly Revenue, 2020
7.15.3 Intodeworld, Inc. Bacteriophage Therapy Product Introduction
7.15.4 Intodeworld, Inc. Response to COVID-19 and Related Developments
7.16 BiomX Ltd.
7.16.1 BiomX Ltd. Business Overview
7.16.2 BiomX Ltd. Bacteriophage Therapy Quarterly Revenue, 2020
7.16.3 BiomX Ltd. Bacteriophage Therapy Product Introduction
7.16.4 BiomX Ltd. Response to COVID-19 and Related Developments
7.17 Phi Therapeutics
7.17.1 Phi Therapeutics Business Overview
7.17.2 Phi Therapeutics Bacteriophage Therapy Quarterly Revenue, 2020
7.17.3 Phi Therapeutics Bacteriophage Therapy Product Introduction
7.17.4 Phi Therapeutics Response to COVID-19 and Related Developments
7.18 Fixed-phage Ltd.
7.18.1 Fixed-phage Ltd. Business Overview
7.18.2 Fixed-phage Ltd. Bacteriophage Therapy Quarterly Revenue, 2020
7.18.3 Fixed-phage Ltd. Bacteriophage Therapy Product Introduction
7.18.4 Fixed-phage Ltd. Response to COVID-19 and Related Developments
7.19 Micreos BV
7.19.1 Micreos BV Business Overview
7.19.2 Micreos BV Bacteriophage Therapy Quarterly Revenue, 2020
7.19.3 Micreos BV Bacteriophage Therapy Product Introduction
7.19.4 Micreos BV Response to COVID-19 and Related Developments
7.20 ContraFect Corporation
7.20.1 ContraFect Corporation Business Overview
7.20.2 ContraFect Corporation Bacteriophage Therapy Quarterly Revenue, 2020
7.20.3 ContraFect Corporation Bacteriophage Therapy Product Introduction
7.20.4 ContraFect Corporation Response to COVID-19 and Related Developments
8 Key Findings
9 Appendix
9.1 About US
9.2 Disclaimer
